The Pasteur Institute of Iran is proud to announce a significant achievement for the Iranian Biomedical Journal (IBJ), as reflected in the latest 2026 report released by the Clarivate analytics group. According to this newly published assessment, the journal has experienced a remarkable increase in its Impact Factor, rising from 1.1 to 1.9. This notable growth represents a substantial leap forward and serves as a clear indicator of the journal's rising quality and influence within the global biomedical research community.

The elevation in Impact Factor is not merely a numerical improvement; it signifies a tangible enhancement in the scientific rigor of the articles published, a marked increase in scholarly citations from researchers worldwide, and the consolidation of IBJ's position as a reputable international platform for biomedical knowledge dissemination. This accomplishment is the direct result of sustained, dedicated efforts and the unwavering collaboration of the journal's esteemed editorial board members, diligent peer reviewers, and the broader community of researchers and scientists across the country. Their commitment to producing and publishing high-caliber research has been instrumental in driving this upward trajectory.

The Iranian Biomedical Journal, published bimonthly by the Pasteur Institute of Iran, operates as an open-access journal which welcomes submissions across a diverse range of cutting-edge fields, including Molecular Microbiology, Molecular Genetics and Genomics, Molecular Immunology and Vaccines, Cancer Biology, Pharmaceutical Biotechnology, Medical Biotechnology, Enzymology and Protein Chemistry, Tissue Engineering, and related interdisciplinary areas. This broad scope reflects the journal's commitment to covering the most dynamic and impactful domains of modern biomedical science.